NasdaqGM:ADMABiotechs
Fraud And Revenue-Recognition Lawsuits Could Be A Game Changer For ADMA Biologics (ADMA)
In recent weeks, ADMA Biologics has been hit with multiple securities class action lawsuits alleging undisclosed related-party transactions, channel stuffing to inflate revenue, and weaknesses in internal controls, following short-seller research and subsequent stock volatility.
These lawsuits focus sharply on how ADMA recognized revenue and distributed its ASCENIV product, putting the company’s prior financial reporting under heightened scrutiny.
We’ll now explore how these fraud and...